Lonza to double production of Covid-19 vaccine at Swiss plant
Lonza has struggled to recruit enough workers to join its Visp plant, which now has three production lines set up and plans three more by early 2022.
Keystone / Olivier Maire
Swiss biotech firm Lonza will add three more production lines to its site in Visp, southwestern Switzerland, to manufacture an active ingredient for the Moderna vaccine, as part of a larger effort to boost the global supply of doses.
This content was published on
2 minutes
swissinfo.ch/SRF/gw
Español
es
Lonza duplicará la producción de la vacuna COVID-19 en su planta suiza
The new production lines will be added gradually to three existing lines and be fully operational by early 2022, Lonza said on Thursday. The two companies signed a ten-year contract in 2020 that enables Lonza to make a drug substance for the mRNA vaccine at its plant for the global market outside the United States.
In a separate press release, Moderna said it planned to increase the overall supply to up to three billion doses by 2022. The firm calculates there will be greater demand for its vaccine as the need for booster shots is likely to grow starting next year.
The announcement comes as Lonza struggles to recruit enough workers to join its Visp plant. Biotech specialists are currently in high demand worldwide as a result of the pandemic, Swiss public television, SRF, reported, adding that the interior ministry is now actively helping Lonza to find specialists from inside the federal administration and universities, including the federal technology institutes ETH Zurich and the EPFL in Lausanne.
Lonza has reportedly recruited temporary staff from food giant Nestlé with help from the Swiss government. Moderna has blamed projected delays in shipments of the vaccine to markets such as the UK and Canada on production bottlenecks, according to Reuters.
Popular Stories
More
Banking & Fintech
UBS releases ‘hundreds’ of staff in fresh wave of job cuts
Should Switzerland take measures to support its struggling industries?
Industrial policies are back in fashion, not only in the United States but also in the EU. Should Switzerland, where various industries are struggling, draw inspiration from such policies?
As a Swiss Abroad, how do you feel about the emergence of more conservative family policies in some US states?
In recent years several US states have adopted more conservative policies on family issues, abortion and education. As a Swiss citizen living there, how do you view this development?
This content was published on
The parents of the young jihadist who left for Syria to join the Islamic State have been given suspended sentences by the Federal Criminal Court.
This content was published on
Felix Lehner, Pamela Rosenkranz and Miroslav Sik have been awarded the Swiss Grand Award for Art/Prix Meret Oppenheim 2025.
Nearly 2% of new Swiss disability insurance claims involve Long Covid
This content was published on
Just under 2% of new claims submitted to the disability insurance between 2021 and 2023 concern people suffering from Long Covid.
This content was published on
The watch industry had to contend with a weakening of its exports last year, which reached a volume of CHF25.9 billion ($28.5 billion).
Swiss firm Lonza to help produce anti-Covid nasal spray in the US
This content was published on
As part of its agreement with American company Altimmune, Lonza will allocate a dedicated manufacturing facility for AdCOVID nasal spray vaccine.
Switzerland mulls future European coordination on medical supplies
This content was published on
“The pandemic has shown us that we are very dependent, maybe too much so, on other markets,” Swiss President Guy Parmelin has said.
Switzerland in race for sufficient Covid immunisation
This content was published on
Health authorities have called for an extra effort from the Swiss population to keep Covid infections as low as possible in the next few months.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.